Hyperfine Forms Neurosurgery Advisory Council
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Hyperfine announced the formation of its Neurosurgery Advisory Council, a multidisciplinary group of neurosurgeons who will provide expertise to help inform the potential role of portable ultra-low-field MRI in neurosurgical applications. "The neurosurgical setting is becoming an important site of care for accessible imaging, where traditional MRI has intrinsic limitations. The Swoop system may open up new possibilities for integrating imaging directly into surgical workflows," said Hyperfine Chief Operating Officer Tom Teisseyre. "Providing access to imaging at key moments around a procedure may help clinical teams make better informed decisions, improve efficiency, and ultimately advance how surgical care is delivered."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HYPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HYPR
Wall Street analysts forecast HYPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.270
Low
2.00
Averages
2.00
High
2.00
Current: 1.270
Low
2.00
Averages
2.00
High
2.00
About HYPR
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hyperfine Launches Next-Gen Swoop® System in Europe
- Global Expansion Milestone: Hyperfine has launched the next-generation Swoop® system in European markets, marking a significant milestone in the global expansion of its advanced portable MRI technology, which is expected to enhance international commercial growth and improve global access to high-quality brain imaging.
- Technological Advancement: The next-gen Swoop® system, powered by the latest Optive AI™ software, delivers transformative image quality that enables faster decision-making support in clinical settings, particularly in remote healthcare services.
- Market Access: The Swoop® system has received CE mark and UKCA approval and has been included in the UniHA procurement listing within the French public healthcare system, which is anticipated to facilitate broader adoption across hospitals and further drive market penetration.
- Commercialization Strategy: Hyperfine plans to make the Model 2 Swoop® system available through distribution partners across all European markets by 2026, which is expected to accelerate its usage and adoption in the U.S., thereby enhancing the company's competitiveness in the global medical imaging market.
See More
Hyperfine Forms Neurosurgery Advisory Council to Enhance Swoop® System Integration
- Advisory Council Formation: Hyperfine has established a Neurosurgery Advisory Council comprising leading neurosurgeons worldwide to evaluate the potential applications of the Swoop® system in neurosurgery, thereby driving the clinical integration and advancement of portable MRI technology.
- Technological Innovation: The Swoop® system, as the first FDA-cleared portable ultra-low-field MRI, provides real-time imaging during surgical procedures, enabling clinical teams to make more informed decisions, enhance surgical efficiency, and improve patient care quality.
- Expert Participation: The council includes neurosurgery experts from renowned medical centers globally, covering various fields such as craniotomy and endovascular neurosurgery, ensuring a multidimensional evaluation of the Swoop® system and sharing of best practices.
- Market Prospects: By collaborating with leading experts in the neurosurgery field, Hyperfine aims to accelerate the application of portable MRI in neurosurgical workflows, expanding its clinical utility to meet the growing healthcare demands.
See More
Accelerating Clinical Use of Portable MRI System
- Clinical Milestone Achieved: Hyperfine's Swoop® system has surpassed 1,000 scans in key hospitals and neurology clinics across the U.S., indicating a significant increase in clinical utilization and adoption, thereby promoting the widespread use of portable MRI in healthcare.
- Significant Economic Benefits: Research from Jefferson Abington Hospital shows that the use of the Swoop® system not only improved patient care but also significantly reduced MRI wait times in the ICU and ED, enhancing hospital operational efficiency and reflecting the economic value of portable MRI.
- Rapid Application Expansion: CHRISTUS Mother Frances Hospital achieved 500 scans in just nine months, demonstrating the successful integration of the Swoop® system into its stroke program, leading to the purchase of additional equipment to enhance emergency patient care and reduce unnecessary admissions and transport costs.
- Optimized Diagnostic Workflow: Neurology of Central Florida has completed over 500 in-office MRI scans, with the introduction of the Swoop® system allowing neurologists to finalize diagnostic evaluations within 24 to 72 hours, significantly shortening patient wait times and improving the timeliness of medical decisions.
See More
Hyperfine Expected to Join Russell 2000 Index
- Index Inclusion Expected: Hyperfine (HYPR) is anticipated to join the Russell 2000 and Russell 3000 indexes after the U.S. market closes on June 26, based on a preliminary list published by FTSE Russell on May 22, indicating increased recognition in the capital markets.
- Strategic Progress: CEO Maria Sainz stated that this inclusion reflects advancements in the company's commercial strategy and the adoption of its portable MRI technology, suggesting enhanced growth potential moving forward.
- Strong Financial Performance: In its Q1 2026 earnings report, Hyperfine reported revenue of $3.90 million, exceeding market expectations by $0.37 million, while the GAAP EPS of -$0.09 indicates a solid gross margin of 50%-55%, showcasing robust profitability.
- Future Revenue Targets: Hyperfine has set a revenue target of $20 million to $22 million for 2026, demonstrating confidence in future growth and reflecting its ongoing innovation and market expansion capabilities in the healthcare technology sector.
See More
Portable MRI Study Shows Efficiency in Emergency Care
- Clinical Trial Results: At the 2026 Annual Meeting of the Society for Academic Emergency Medicine, Hyperfine presented results from the PRIME study, demonstrating that portable MRI significantly enhances imaging efficiency in emergency departments by reducing the median time from imaging order to scan start from 7.76 hours to 1.28 hours, a difference of 6.35 hours, highlighting its potential value in urgent situations.
- Critical Pathology Detection: Among completed scans, 18.6% revealed critical pathologies such as acute ischemic stroke and mass lesions, which were successfully detected by portable MRI and confirmed by conventional MRI, underscoring its importance in rapid diagnosis.
- Workflow Optimization: The study indicates that portable MRI can be integrated into emergency department workflows more swiftly, alleviating patient boarding delays associated with waiting for conventional MRI, thereby enhancing overall care efficiency for emergency teams.
- Future Development Potential: Hyperfine's Swoop® system, by providing faster imaging services, may transform emergency medicine, assisting clinicians in accessing actionable imaging information sooner and advancing the field of emergency neuroimaging.
See More
Hyperfine, Inc. Reports Q1 2026 Earnings Highlights
- Significant Revenue Growth: Hyperfine reported Q1 2026 revenue of $3.9 million with a gross margin of 51%, demonstrating effective execution in both growth and cost control, thereby enhancing its competitive position in the market.
- International Expansion Progress: The company obtained CE and UKCA marks for its next-generation Swoop system and DWI Optive AI software, with plans to launch in Europe in Q3, further broadening its international business footprint.
- Increased Product Adoption: The advanced DWI Optive AI software is now implemented in most scanners, with unit sales rising from 6 to 10 compared to the prior year, indicating accelerated penetration in the large customer market.
- Stable Financial Outlook: Management reiterated full-year revenue expectations between $20 million and $22 million, with gross margins projected to remain between 50% and 55%, and cash burn controlled at $26 million to $28 million, reflecting confidence in future performance.
See More
Hyperfine Launches Next-Gen Swoop® System in Europe
- Global Expansion Milestone: Hyperfine has launched the next-generation Swoop® system in European markets, marking a significant milestone in the global expansion of its advanced portable MRI technology, which is expected to enhance international commercial growth and improve global access to high-quality brain imaging.
- Technological Advancement: The next-gen Swoop® system, powered by the latest Optive AI™ software, delivers transformative image quality that enables faster decision-making support in clinical settings, particularly in remote healthcare services.
- Market Access: The Swoop® system has received CE mark and UKCA approval and has been included in the UniHA procurement listing within the French public healthcare system, which is anticipated to facilitate broader adoption across hospitals and further drive market penetration.
- Commercialization Strategy: Hyperfine plans to make the Model 2 Swoop® system available through distribution partners across all European markets by 2026, which is expected to accelerate its usage and adoption in the U.S., thereby enhancing the company's competitiveness in the global medical imaging market.
See More
Hyperfine Forms Neurosurgery Advisory Council to Enhance Swoop® System Integration
- Advisory Council Formation: Hyperfine has established a Neurosurgery Advisory Council comprising leading neurosurgeons worldwide to evaluate the potential applications of the Swoop® system in neurosurgery, thereby driving the clinical integration and advancement of portable MRI technology.
- Technological Innovation: The Swoop® system, as the first FDA-cleared portable ultra-low-field MRI, provides real-time imaging during surgical procedures, enabling clinical teams to make more informed decisions, enhance surgical efficiency, and improve patient care quality.
- Expert Participation: The council includes neurosurgery experts from renowned medical centers globally, covering various fields such as craniotomy and endovascular neurosurgery, ensuring a multidimensional evaluation of the Swoop® system and sharing of best practices.
- Market Prospects: By collaborating with leading experts in the neurosurgery field, Hyperfine aims to accelerate the application of portable MRI in neurosurgical workflows, expanding its clinical utility to meet the growing healthcare demands.
See More
Accelerating Clinical Use of Portable MRI System
- Clinical Milestone Achieved: Hyperfine's Swoop® system has surpassed 1,000 scans in key hospitals and neurology clinics across the U.S., indicating a significant increase in clinical utilization and adoption, thereby promoting the widespread use of portable MRI in healthcare.
- Significant Economic Benefits: Research from Jefferson Abington Hospital shows that the use of the Swoop® system not only improved patient care but also significantly reduced MRI wait times in the ICU and ED, enhancing hospital operational efficiency and reflecting the economic value of portable MRI.
- Rapid Application Expansion: CHRISTUS Mother Frances Hospital achieved 500 scans in just nine months, demonstrating the successful integration of the Swoop® system into its stroke program, leading to the purchase of additional equipment to enhance emergency patient care and reduce unnecessary admissions and transport costs.
- Optimized Diagnostic Workflow: Neurology of Central Florida has completed over 500 in-office MRI scans, with the introduction of the Swoop® system allowing neurologists to finalize diagnostic evaluations within 24 to 72 hours, significantly shortening patient wait times and improving the timeliness of medical decisions.
See More
Hyperfine Expected to Join Russell 2000 Index
- Index Inclusion Expected: Hyperfine (HYPR) is anticipated to join the Russell 2000 and Russell 3000 indexes after the U.S. market closes on June 26, based on a preliminary list published by FTSE Russell on May 22, indicating increased recognition in the capital markets.
- Strategic Progress: CEO Maria Sainz stated that this inclusion reflects advancements in the company's commercial strategy and the adoption of its portable MRI technology, suggesting enhanced growth potential moving forward.
- Strong Financial Performance: In its Q1 2026 earnings report, Hyperfine reported revenue of $3.90 million, exceeding market expectations by $0.37 million, while the GAAP EPS of -$0.09 indicates a solid gross margin of 50%-55%, showcasing robust profitability.
- Future Revenue Targets: Hyperfine has set a revenue target of $20 million to $22 million for 2026, demonstrating confidence in future growth and reflecting its ongoing innovation and market expansion capabilities in the healthcare technology sector.
See More
Portable MRI Study Shows Efficiency in Emergency Care
- Clinical Trial Results: At the 2026 Annual Meeting of the Society for Academic Emergency Medicine, Hyperfine presented results from the PRIME study, demonstrating that portable MRI significantly enhances imaging efficiency in emergency departments by reducing the median time from imaging order to scan start from 7.76 hours to 1.28 hours, a difference of 6.35 hours, highlighting its potential value in urgent situations.
- Critical Pathology Detection: Among completed scans, 18.6% revealed critical pathologies such as acute ischemic stroke and mass lesions, which were successfully detected by portable MRI and confirmed by conventional MRI, underscoring its importance in rapid diagnosis.
- Workflow Optimization: The study indicates that portable MRI can be integrated into emergency department workflows more swiftly, alleviating patient boarding delays associated with waiting for conventional MRI, thereby enhancing overall care efficiency for emergency teams.
- Future Development Potential: Hyperfine's Swoop® system, by providing faster imaging services, may transform emergency medicine, assisting clinicians in accessing actionable imaging information sooner and advancing the field of emergency neuroimaging.
See More
Hyperfine, Inc. Reports Q1 2026 Earnings Highlights
- Significant Revenue Growth: Hyperfine reported Q1 2026 revenue of $3.9 million with a gross margin of 51%, demonstrating effective execution in both growth and cost control, thereby enhancing its competitive position in the market.
- International Expansion Progress: The company obtained CE and UKCA marks for its next-generation Swoop system and DWI Optive AI software, with plans to launch in Europe in Q3, further broadening its international business footprint.
- Increased Product Adoption: The advanced DWI Optive AI software is now implemented in most scanners, with unit sales rising from 6 to 10 compared to the prior year, indicating accelerated penetration in the large customer market.
- Stable Financial Outlook: Management reiterated full-year revenue expectations between $20 million and $22 million, with gross margins projected to remain between 50% and 55%, and cash burn controlled at $26 million to $28 million, reflecting confidence in future performance.
See More
